As AbbVie’s Challenge Falters, Vertex Looks To Build On CF Dominance

Blockbuster Potential In Late-Stage Pipeline

 
• By Andrew McConaghie
  
Vertex Mobile
Vertex's CF sales are set to reach $8.5bn this year, but investors are already looking ahead to opportunities in new therapy areas. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip